Related Experiment Video
Updated: May 22, 2026
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
Identification of a novel vasoconstrictor peptide specific for the systemic circulation
Daniela Wenzel1, Manuel Koch, Michaela Matthey
1Institute of Physiology I, University of Bonn, Bonn, Germany. bernd.fleischmann@uni-bonn.de
Hypertension (Dallas, Tex. : 1979)
|May 2, 2012
Summary
The laminin nonapeptide (LNP) CDPGYIGSR acts as a vasoconstrictive agent, narrowing blood vessels. This novel peptide specifically targets systemic arteries, impacting vascular tone through calcium influx in smooth muscle cells.
Area of Science:
- Cardiovascular Biology
- Molecular Pharmacology
- Vascular Physiology
Background:
- Small molecular weight peptides can exhibit significant vasoactive properties.
- The specific peptides involved in regulating vascular tone are not fully elucidated.
Purpose of the Study:
- To identify and characterize novel vasoactive peptides.
- To investigate the vasoconstrictive potential of the laminin nonapeptide (LNP) CDPGYIGSR.
Main Methods:
- Isometric force measurements in murine and human arteries.
- [Ca(2+)](i) imaging and patch clamp electrophysiology in vascular smooth muscle cells.
- In vivo catheter measurements and ex vivo perfused lung system assays in mice.
Main Results:
- LNP induced dose-dependent vasoconstriction in murine and human systemic arteries.
- LNP triggered transmembrane calcium influx by activating nonselective cation channels in vascular smooth muscle cells.
- In vivo and ex vivo studies confirmed LNP's vasoconstrictive effect was specific to the systemic circulation, with no impact on pulmonary arteries.
Conclusions:
- The laminin nonapeptide (LNP) CDPGYIGSR is a novel vasoconstrictive agent.
- LNP's mechanism involves calcium influx and channel activation in vascular smooth muscle.
- LNP's vasoactivity is confined to the systemic vasculature.
